Last reviewed · How we verify
Quadrivalent Influenza Standard Dose Vaccine
Quadrivalent Influenza Standard Dose Vaccine is a Biologic drug developed by Sanofi Pasteur, a Sanofi Company. It is currently in Phase 1 development. Also known as: Fluzone Qudrivalent®.
At a glance
| Generic name | Quadrivalent Influenza Standard Dose Vaccine |
|---|---|
| Also known as | Fluzone Qudrivalent® |
| Sponsor | Sanofi Pasteur, a Sanofi Company |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Influenza Vaccination Strategy for Patients With Hematologic Malignancy (PHASE3)
- A Study to Evaluate the Intratumoral Influenza Vaccine Administration in Patients With Breast Cancer (PHASE1)
- High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients (PHASE2)
- Study on a High-Dose Quadrivalent Influenza Vaccine Compared With Standard-Dose Quadrivalent Influenza Vaccine in Children 6 Months Through 35 Months of Age (PHASE3)
- High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients (PHASE2)
- Randomized Influenza Vaccine Evaluation of Immune Response (PHASE4)
- Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Taiwanese Adults 65 Years of Age and Older (PHASE3)
- Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Japanese Adults 60 Years of Age and Older (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Quadrivalent Influenza Standard Dose Vaccine CI brief — competitive landscape report
- Quadrivalent Influenza Standard Dose Vaccine updates RSS · CI watch RSS
- Sanofi Pasteur, a Sanofi Company portfolio CI
Frequently asked questions about Quadrivalent Influenza Standard Dose Vaccine
What is Quadrivalent Influenza Standard Dose Vaccine?
Quadrivalent Influenza Standard Dose Vaccine is a Biologic drug developed by Sanofi Pasteur, a Sanofi Company.
Who makes Quadrivalent Influenza Standard Dose Vaccine?
Quadrivalent Influenza Standard Dose Vaccine is developed by Sanofi Pasteur, a Sanofi Company (see full Sanofi Pasteur, a Sanofi Company pipeline at /company/sanofi).
Is Quadrivalent Influenza Standard Dose Vaccine also known as anything else?
Quadrivalent Influenza Standard Dose Vaccine is also known as Fluzone Qudrivalent®.
What development phase is Quadrivalent Influenza Standard Dose Vaccine in?
Quadrivalent Influenza Standard Dose Vaccine is in Phase 1.
Related
- Manufacturer: Sanofi Pasteur, a Sanofi Company — full pipeline
- Also known as: Fluzone Qudrivalent®
- Compare: Quadrivalent Influenza Standard Dose Vaccine vs similar drugs
- Pricing: Quadrivalent Influenza Standard Dose Vaccine cost, discount & access